首页> 外文期刊>Molecules >Long-Term Stability of New Co-Amorphous Drug Binary Systems: Study of Glass Transitions as a Function of Composition and Shelf Time
【24h】

Long-Term Stability of New Co-Amorphous Drug Binary Systems: Study of Glass Transitions as a Function of Composition and Shelf Time

机译:新的无定形药物二元体系的长期稳定性:玻璃化转变与组成和保存时间的关系研究

获取原文
           

摘要

The amorphous state is of particular interest in the pharmaceutical industry due to the higher solubility that amorphous active pharmaceutical ingredients show compared to their respective crystalline forms. Due to their thermodynamic instability, drugs in the amorphous state tend to recrystallize; in order to avoid crystallization, it has been a common strategy to add a second component to hinder the crystalline state and form a thermally stable co-amorphous system, that is to say, an amorphous binary system which retains its amorphous structure. The second component can be a small molecule excipient (such as a sugar or an aminoacid) or a second drug, with the advantage that a second active pharmaceutical ingredient could be used for complementary or combined therapeutic purposes. In most cases, the compositions studied are limited to 1:1, 2:1 and 1:2 molar ratios, leaving a gap of information about phase transitions and stability on the amorphous state in a wider range of compositions. In the present work, a study of novel co–amorphous formulations in which the selection of the active pharmaceutical ingredients was made according to the therapeutic effect is presented. Resistance against crystallization and behavior of glass transition temperature ( T g were studied through calorimetric measurements as a function of composition and shelf time. It was found that binary formulations with T g temperatures higher than those of pure components presented long-term thermal stability. In addition, significant increments of T g values, of as much as 15 ° C, were detected as a result of glass relaxation at room temperature during storage time; this behavior of glass transition has not been previously reported for co-amorphous drugs. Based on these results, it can be concluded that monitoring behavior of T g and relaxation processes during the first weeks of storage leads to a more objective evaluation of the thermomechanical stability of an amorphous formulation. View Full-Text
机译:由于无定形活性药物成分显示出比其各自的结晶形式更高的溶解度,因此无定形状态在制药工业中特别受关注。由于其热力学不稳定性,处于无定形状态的药物易于重结晶。为了避免结晶,通常的策略是添加第二种组分以阻碍晶态并形成热稳定的共非晶体系,即保持其非晶结构的非晶二元体系。第二组分可以是小分子赋形剂(例如糖或氨基酸)或第二药物,其优点在于第二活性药物成分可以用于互补或联合治疗目的。在大多数情况下,所研究的组成仅限于1:1、2:1和1:2的摩尔比,因此在更广泛的组成范围内,仍存在有关相变和非晶态稳定性的信息空白。在目前的工作中,对新型共非晶制剂的研究进行了研究,其中根据治疗效果选择了活性药物成分。通过量热测量研究了其抗结晶性和玻璃化转变温度的行为(T g与组成和保存时间的关系)。发现,T g温度高于纯组分的二元配方具有长期的热稳定性。此外,由于室温下玻璃在储存时间内的弛豫,可检测到T g值显着增加,最高可达15°C;以前对于共非晶药物尚未报道这种玻璃化转变的行为。这些结果可以得出结论,在储存的最初几周内监测T g和松弛过程的行为,可以对无定形制剂的热机械稳定性进行更客观的评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号